MRNA

Moderna Inc. Healthcare - Biotechnology Investor Relations →

YES
56.2% BELOW
↓ Approaching Was -53.2% last week
-15% -10% -5% 0% 5% 10% 15%+
Buy Threshold $93.60
14-Week RSI 66

Moderna Inc. (MRNA) closed at $41.01 as of 2026-02-02, trading 56.2% below its 200-week moving average of $93.60. This places MRNA in the extreme value zone. The stock is currently moving closer to the line, down from -53.2% last week. The 14-week RSI sits at 66, indicating neutral momentum.

Over the past 326 weeks of data, MRNA has crossed below its 200-week moving average 2 times. On average, these episodes lasted 74 weeks. Historically, investors who bought MRNA at the start of these episodes saw an average one-year return of +858.5%.

With a market cap of $16.0 billion, MRNA is a large-cap stock. Free cash flow yield is currently negative, meaning the company is burning cash. Return on equity stands at -29.3%. The stock trades at 1.7x book value.

Over the past 6.3 years, a hypothetical investment of $100 in MRNA would have grown to $201, compared to $241 for the S&P 500. MRNA has returned 11.7% annualized vs 14.9% for the index, underperforming the broader market over this period.

In the past 12 months, corporate insiders have made 2 open-market purchases totaling $6,008,569. Notably, these purchases occurred while MRNA is trading below its 200-week moving average — insiders are buying when the market is most pessimistic.

Free cash flow has been declining at a -100% compound annual rate. A deteriorating cash flow trend warrants extra scrutiny — the stock may be cheap for a reason.

Growth of $100: MRNA vs S&P 500

Monthly data normalized to $100 at start. Vertical dashed lines mark 200-week MA touches.

What Happens After MRNA Crosses Below the Line?

Across 2 historical episodes, buying MRNA when it crossed below its 200-week moving average produced an average return of +245.5% after 12 months (median +497.0%), compared to +26.5% for the S&P 500 over the same periods. 50% of those episodes were profitable after one year. After 24 months, the average return was +173.5% vs +44.5% for the index.

Each line shows $100 invested at the moment MRNA crossed below its 200-week MA. Bold blue = stock average. Gray dashed = S&P 500 average over same periods.

Advertisement

Insider Buying Activity

1 conviction buy in the past 12 months (purchases over $500K with meaningful position increases).

DateInsiderTitleValueSharesPosition +%
2025-03-03BANCEL STEPHANE JChief Executive Officer$5,004,318160,314+0.7%

Historical Touches

MRNA has crossed below its 200-week MA 2 times with an average 1-year return of +858.5% after recovery.

Crossed BelowRecoveredWeeksMax Depth1-Year ReturnReturn Since Touch
Feb 2020Feb 202010.8%+858.5%+125.0%
Apr 2023Ongoing146+82.9%Ongoing-69.1%
Average74+858.5%

Not financial advice. This is an educational tool. Past performance does not guarantee future results. Do your own research before making investment decisions.

Data as of Friday close, 2026-02-02